{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:27:32Z","timestamp":1793424452227,"version":"4.5.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T00:00:00Z","timestamp":1733875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jacadv.2024.101549","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T20:01:35Z","timestamp":1736452895000},"page":"101549","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Impact of Proprotein Convertase Subtilisin\/Kexin Type 9 Inhibitors on\u00a0Lipoprotein(a)"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9100-0724","authenticated-orcid":false,"given":"Frederick Berro","family":"Rivera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Whoy","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cruz","family":"Linnaeus Louisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genquen Philip","family":"Carado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Vincent","family":"Magalong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent Anthony","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Grace","family":"Enriquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0735-9756","authenticated-orcid":false,"given":"Martha","family":"Gulati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byambaa","family":"Enkhmaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Pagidipati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishant P.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jacadv.2024.101549_bib1","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/cvr\/cvu107","article-title":"Lipoprotein (a) concentrations, apolipoprotein (a) phenotypes, and peripheral arterial disease in three independent cohorts","volume":"103","author":"Laschkolnig","year":"2014","journal-title":"Cardiovasc Res"},{"issue":"12","key":"10.1016\/j.jacadv.2024.101549_bib2","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1161\/ATVBAHA.112.255521","article-title":"Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC Norfolk prospective population study","volume":"32","author":"Gurdasani","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacadv.2024.101549_bib3","unstructured":"Schmidt K, Noureen A, Kronenberg FA-O, et\u00a0al. Structure, function, and genetics of lipoprotein (a) A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies Lipoprotein(a): the revenant Lipoprotein(a) Gets Worse Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies Lipoprotein(a). Elsevier. 1539-7262."},{"issue":"4","key":"10.1016\/j.jacadv.2024.101549_bib4","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/00041433-200208000-00006","article-title":"Lipoprotein(a): still an enigma?","volume":"13","author":"Kostner","year":"2002","journal-title":"Curr Opin Lipidol"},{"issue":"39","key":"10.1016\/j.jacadv.2024.101549_bib5","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.jacadv.2024.101549_bib6","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","article-title":"Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American heart association","volume":"42","author":"Reyes-Soffer","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"10.1016\/j.jacadv.2024.101549_bib7","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O'Donoghue","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2024.101549_bib8","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.atherosclerosis.2021.11.019","article-title":"High lipoprotein(a) is associated with major adverse limb events after femoral artery endarterectomy","volume":"349","author":"Verwer","year":"2022","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.jacadv.2024.101549_bib9","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.116.025253","article-title":"Effects of PCSK9 inhibition with alirocumab on lipoprotein metabolism in healthy humans","volume":"135","author":"Reyes-Soffer","year":"2017","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.jacadv.2024.101549_bib10","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome","volume":"75","author":"Bittner","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2024.101549_bib11","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jacadv.2024.101549_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.jacadv.2024.101549_bib13","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1007\/s00120-021-01471-2","article-title":"[How to interpret the certainty of evidence based on GRADE (Grading of recommendations, assessment, development and evaluation)]","volume":"60","author":"Schwingshackl","year":"2021","journal-title":"Urologe"},{"key":"10.1016\/j.jacadv.2024.101549_bib14","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jclinepi.2018.01.003","article-title":"Registration in the international prospective register of systematic reviews (PROSPERO) of systematic review protocols was associated with increased review quality","volume":"100","author":"Sideri","year":"2018","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"4","key":"10.1016\/j.jacadv.2024.101549_bib15","doi-asserted-by":"crossref","first-page":"e010932","DOI":"10.1161\/JAHA.118.010932","article-title":"Relationship between low-density lipoprotein cholesterol and lipoprotein(a) lowering in response to PCSK9 inhibition with evolocumab","volume":"8","author":"Shapiro","year":"2019","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"10","key":"10.1016\/j.jacadv.2024.101549_bib16","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1253\/circj.CJ-19-0412","article-title":"Effect of alirocumab on coronary atheroma volume in Japanese patients with acute coronary syndrome \u2014 the ODYSSEY J-IVUS trial","volume":"83","author":"Ako","year":"2019","journal-title":"Circ J"},{"issue":"8","key":"10.1016\/j.jacadv.2024.101549_bib17","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1210\/jc.2015-1520","article-title":"Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial","volume":"100","author":"Bays","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"19","key":"10.1016\/j.jacadv.2024.101549_bib18","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","article-title":"A\u00a052-week placebo-controlled trial of evolocumab in hyperlipidemia","volume":"370","author":"Blom","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.jacadv.2024.101549_bib19","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jacc.2020.05.027","article-title":"Efficacy and safety of alirocumab in adults with homozygous familial hypercholesterolemia: the ODYSSEY HoFH trial","volume":"76","author":"Blom","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"20","key":"10.1016\/j.jacadv.2024.101549_bib20","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1016\/j.jacc.2020.03.025","article-title":"Evolocumab in HIV-infected patients with dyslipidemia: primary results of the randomized, double-blind BEIJERINCK study","volume":"75","author":"Boccara","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"19","key":"10.1016\/j.jacadv.2024.101549_bib21","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/eurheartj\/ehv028","article-title":"Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial","volume":"36","author":"Cannon","year":"2015","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.jacadv.2024.101549_bib22","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/JCMA.0000000000000062","article-title":"A\u00a0subanalysis of Taiwanese patients from ODYSSEY South Korea and Taiwan study evaluating the efficacy and safety of alirocumab","volume":"82","author":"Chao","year":"2019","journal-title":"J\u00a0Chin Med Assoc"},{"key":"10.1016\/j.jacadv.2024.101549_bib23","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.atherosclerosis.2015.11.010","article-title":"Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: the ODYSSEY OPTIONS II randomized trial","volume":"244","author":"Farnier","year":"2016","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1016\/j.jacadv.2024.101549_bib24","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10557-016-6685-y","article-title":"Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia and LDL-C of 160\u00a0mg\/dl or higher","volume":"30","author":"Ginsberg","year":"2016","journal-title":"Cardiovasc Drugs Ther"},{"issue":"1","key":"10.1016\/j.jacadv.2024.101549_bib25","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jacl.2019.10.015","article-title":"Odyssey EAST: alirocumab efficacy and safety vs ezetimibe in high cardiovascular risk patients with hypercholesterolemia and on maximally tolerated statin in China, India, and Thailand","volume":"14","author":"Han","year":"2020","journal-title":"J\u00a0Clin Lipidol"},{"issue":"4","key":"10.1016\/j.jacadv.2024.101549_bib26","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1536\/ihj.22-052","article-title":"Effect of the early application of evolocumab on blood lipid profile and cardiovascular prognosis in patients with extremely high-risk acute coronary syndrome","volume":"63","author":"Hao","year":"2022","journal-title":"Int Heart J"},{"issue":"5","key":"10.1016\/j.jacadv.2024.101549_bib27","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1253\/circj.CJ-14-0130","article-title":"Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk--primary results from the phase 2 YUKAWA study","volume":"78","author":"Hirayama","year":"2014","journal-title":"Circ J"},{"key":"10.1016\/j.jacadv.2024.101549_bib28","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.atherosclerosis.2021.06.913","article-title":"Alirocumab treatment and neurocognitive function according to the CANTAB scale in patients at increased cardiovascular risk: a prospective, randomized, placebo-controlled study","volume":"331","author":"Janik","year":"2021","journal-title":"Atherosclerosis"},{"issue":"43","key":"10.1016\/j.jacadv.2024.101549_bib29","first-page":"2996","article-title":"ODYSSEY FH I and FH II: 78\u00a0week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia","volume":"36","author":"Kastelein","year":"2015","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.jacadv.2024.101549_bib30","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.ahj.2015.03.004","article-title":"Efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study","volume":"169","author":"Kereiakes","year":"2015","journal-title":"Am Heart J"},{"issue":"1","key":"10.1016\/j.jacadv.2024.101549_bib31","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.amjcard.2015.10.021","article-title":"A\u00a0phase 3 study of evolocumab (AMG 145) in statin-treated Japanese patients at high cardiovascular risk","volume":"117","author":"Kiyosue","year":"2016","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.jacadv.2024.101549_bib32","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jacl.2017.09.007","article-title":"A\u00a0randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT)","volume":"12","author":"Koh","year":"2018","journal-title":"J\u00a0Clin Lipidol"},{"issue":"9858","key":"10.1016\/j.jacadv.2024.101549_bib33","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/S0140-6736(12)61771-1","article-title":"Efficacy, safety, and tolerability of a monoclonal antibody\u00a0to proprotein convertase subtilisin\/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo controlled, phase 2 study","volume":"380","author":"Koren","year":"2012","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.jacadv.2024.101549_bib34","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.jacc.2014.03.018","article-title":"Anti PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab","volume":"63","author":"Koren","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"20","key":"10.1016\/j.jacadv.2024.101549_bib35","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1016\/j.jacc.2019.08.010","article-title":"Evolocumab for early reduction of LDL cholesterol levels in patients with acute coronary syndromes (EVOPACS)","volume":"74","author":"Koskinas","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.jacadv.2024.101549_bib36","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.diabet.2017.01.004","article-title":"Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: rationale and design of the ODYSSEY DM-INSULIN trial","volume":"43","author":"Cariou","year":"2017","journal-title":"Diabetes Metab"},{"issue":"9","key":"10.1016\/j.jacadv.2024.101549_bib37","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/clc.23018","article-title":"Rationale and design of a randomized study to assess the efficacy and safety of evolocumab in patients with diabetes and dyslipidemia: the BERSON clinical trial","volume":"41","author":"Lorenzatti","year":"2018","journal-title":"Clin Cardiol"},{"issue":"25","key":"10.1016\/j.jacadv.2024.101549_bib38","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/j.jacc.2012.03.007","article-title":"Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease, SAR236553\/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy","volume":"59","author":"McKenney","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.jacadv.2024.101549_bib39","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","article-title":"Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial","volume":"9","author":"Moriarty","year":"2015","journal-title":"J\u00a0Clin Lipidol"},{"issue":"12 suppl 4","key":"10.1016\/j.jacadv.2024.101549_bib40","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.3949\/ccjm.84.s4.01","article-title":"Results of the GLAGOV trial","volume":"84","author":"Nissen","year":"2017","journal-title":"CCJM"},{"issue":"15","key":"10.1016\/j.jacadv.2024.101549_bib41","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2016.3608","article-title":"Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial","volume":"315","author":"Nissen","year":"2016","journal-title":"JAMA"},{"issue":"20","key":"10.1016\/j.jacadv.2024.101549_bib42","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.112.144055","volume":"126","author":"Raal","year":"2012","journal-title":"Circulation"},{"issue":"9965","key":"10.1016\/j.jacadv.2024.101549_bib43","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"issue":"9965","key":"10.1016\/j.jacadv.2024.101549_bib44","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.jacadv.2024.101549_bib45","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1001\/jama.2014.4030","article-title":"Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial","volume":"311","author":"Robinson","year":"2014","journal-title":"JAMA"},{"issue":"16","key":"10.1016\/j.jacadv.2024.101549_bib46","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.jacadv.2024.101549_bib47","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1007\/s00125-019-4856-7","article-title":"Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study","volume":"62","author":"Rosenson","year":"2019","journal-title":"Diabetologia"},{"issue":"20","key":"10.1016\/j.jacadv.2024.101549_bib48","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1056\/NEJMoa1201832","article-title":"Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia","volume":"367","author":"Roth","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.jacadv.2024.101549_bib49","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2217\/fca.14.82","article-title":"ODYSSEY MONO: effect of alirocumab 75\u00a0mg subcutaneously every 2\u00a0weeks as monotherapy versus ezetimibe over 24\u00a0weeks","volume":"11","author":"Roth","year":"2015","journal-title":"Future Cardiol"},{"key":"10.1016\/j.jacadv.2024.101549_bib50","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.atherosclerosis.2016.08.043","article-title":"A\u00a0phase III randomized trial evaluating alirocumab 300\u00a0mg every 4\u00a0weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I","volume":"254","author":"Roth","year":"2016","journal-title":"Atherosclerosis"},{"issue":"18","key":"10.1016\/j.jacadv.2024.101549_bib51","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with\u00a0cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.jacadv.2024.101549_bib52","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"9836","key":"10.1016\/j.jacadv.2024.101549_bib53","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(12)60771-5","volume":"380","author":"Stein","year":"2012","journal-title":"Lancet"},{"issue":"33","key":"10.1016\/j.jacadv.2024.101549_bib54","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1093\/eurheartj\/ehy862","article-title":"Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low density lipoprotein cholesterol reduction by proprotein convertase subtilisin\/kexin type 9 antibody treatment","volume":"40","author":"Stiekema","year":"2019","journal-title":"Eur Heart J"},{"issue":"23","key":"10.1016\/j.jacadv.2024.101549_bib55","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","article-title":"Anti PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab","volume":"63","author":"Stroes","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.jacadv.2024.101549_bib56","doi-asserted-by":"crossref","first-page":"e003421","DOI":"10.1161\/JAHA.116.003421","article-title":"Efficacy and safety of alirocumab 150\u00a0mg every 4 Weeks in patients with hypercholesterolemia not on statin therapy: the ODYSSEY CHOICE II study","volume":"5","author":"Stroes","year":"2016","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"23","key":"10.1016\/j.jacadv.2024.101549_bib57","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/jama.2012.25790","article-title":"Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial","volume":"308","author":"Sullivan","year":"2012","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.jacadv.2024.101549_bib58","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1253\/circj.CJ-16-0387","article-title":"Efficacy and safety of alirocumab in Japanese patients with heterozygous familial hypercholesterolemia or at high cardiovascular risk with hypercholesterolemia not adequately controlled with statins - ODYSSEY Japan randomized controlled trial","volume":"80","author":"Teramoto","year":"2016","journal-title":"Circ J"},{"issue":"3","key":"10.1016\/j.jacadv.2024.101549_bib59","first-page":"218","article-title":"Efficacy and safety of alirocumab 150mg every 4\u00a0weeks in hypercholesterolemic patients on non-statin lipid-lowering therapy or lowest strength dose of statin: ODYSSEY NIPPON","volume":"73","author":"Teramoto","year":"2019","journal-title":"J\u00a0Cardiol"},{"issue":"4","key":"10.1016\/j.jacadv.2024.101549_bib60","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.116.025080","article-title":"Factorial effects of evolocumab and atorvastatin on lipoprotein metabolism","volume":"135","author":"Watts","year":"2017","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.jacadv.2024.101549_bib61","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1186\/s12872-022-02932-y","article-title":"Effect of an increase in Lp(a) following statin therapy on cardiovascular prognosis in secondary prevention population of coronary artery disease [published correction appears in BMC Cardiovasc Disord. 2022 Dec 30;22(1):577","volume":"22","author":"Zhu","year":"2022","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.jacadv.2024.101549_bib62","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1093\/eurheartj\/ehy122","article-title":"Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics","volume":"39","author":"Watts","year":"2018","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.jacadv.2024.101549_bib63","doi-asserted-by":"crossref","first-page":"376","DOI":"10.7326\/M17-2485","article-title":"Diagnosing resistance to a proprotein convertase subtilisin\/kexin type 9 inhibitor","volume":"168","author":"Shapiro","year":"2018","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.jacadv.2024.101549_bib64","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11883-021-00951-2","article-title":"Lipoprotein (a): when to measure and how to treat?","volume":"23","author":"Rhainds","year":"2021","journal-title":"Curr Atherosclerosis Rep"},{"issue":"3","key":"10.1016\/j.jacadv.2024.101549_bib65","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/FJC.0000000000000963","article-title":"Lipoprotein(a) reduction with proprotein convertase subtilisin\/kexin type 9 inhibitors: a systematic review and meta-analysis","volume":"77","author":"Farmakis","year":"2021","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"issue":"6","key":"10.1016\/j.jacadv.2024.101549_bib66","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/FJC.0000000000001419","article-title":"Effect of different types and dosages of proprotein convertase subtilisin\/kexin type 9 inhibitors on lipoprotein(a) levels: a network meta-analysis","volume":"81","author":"Yu","year":"2023","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"issue":"1","key":"10.1016\/j.jacadv.2024.101549_bib67","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1161\/ATVBAHA.119.312951","article-title":"Lipoprotein(a)- lowering by 50\u00a0mg\/dL (105\u00a0nmol\/L) may Be needed to reduce cardiovascular disease 20% in secondary prevention: a population-based study","volume":"40","author":"Madsen","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X24008305?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X24008305?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T03:18:31Z","timestamp":1768965511000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X24008305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":67,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2772963X24008305"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2024.101549","relation":{},"ISSN":["2772-963X"],"issn-type":[{"value":"2772-963X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Proprotein Convertase Subtilisin\/Kexin Type 9 Inhibitors on\u00a0Lipoprotein(a)","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2024.101549","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"101549"}}